Effects of Atypical Protein Kinase C Inhibitor (DNDA) on Lung Cancer Proliferation and Migration by PKC-ι/FAK Ubiquitination Through the Cbl-b Pathway

PURPOSE: The options for treating lung cancers are limited, as diagnosis typically occurs during the late stages of the disease. There is a dire need to develop aPKC (atypical Protein Kinase C) inhibitors due to aPKC overexpression and contributions to lung cancer malignancies. In this study, we inv...

Descripción completa

Detalles Bibliográficos
Autores principales: BommaReddy, Raja Reddy, Patel, Rekha, Smalley, Tracess, Acevedo-Duncan, Mildred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047975/
https://www.ncbi.nlm.nih.gov/pubmed/32158232
http://dx.doi.org/10.2147/OTT.S224866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047975/
https://www.ncbi.nlm.nih.gov/pubmed/32158232
http://dx.doi.org/10.2147/OTT.S224866

Ejemplares similares